Compared with a contemporary zotarolimus drug-eluting stent, a coronary bioadaptor system is noninferior among patients with CAD receiving PCI.
Zacks.com on MSN3d
If You Invested $1000 in Boston Scientific a Decade Ago, This is How Much It'd Be Worth NowThe company is one of the leading players in the interventional cardiology market with its coronary stent product offerings. Boston Scientific markets a broad portfolio of internally-developed and ...
At the same time, metal-free percutaneous coronary intervention (PCI) and Drug-Eluting Balloons (DEB) present new possibilities for treating complex lesions without leaving permanent stents behind.
Solaris Endovascular today announced its formation to develop solutions for dialysis access and treating peripheral artery ...
HealthDay on MSN11d
Delaying Noncardiac Surgery for Several Months After Heart Attack Found to Be SaferDelaying noncardiac surgeries for three to six months following a heart attack appears safer for those who undergo ...
Solaris Endovascular, Inc. recently announced the formation of the company, which will develop solutions for dialysis access i ...
The following is a summary of “Evaluation of Small Vessel Bifurcation Stenting Using the Double-Kissing Culotte and Culotte ...
The global Implantable Drug Eluting Devices Market is poised for substantial growth, projected to expand at a compound annual growth rate (CAGR) of 6.0% from 2022 to 2029. The market, valued at ...
Solaris Endovascular Inc Solaris SX Flexibility NEW ORLEANS, LA, UNITED STATES, November 13, 2024 /EINPresswire / -- Solaris Endova ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback